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Background
The use of transcatheter aortic-valve replacement has been shown to reduce mortality 
among high-risk patients with aortic stenosis who are not candidates for surgical 
replacement. However, the two procedures have not been compared in a randomized 
trial involving high-risk patients who are still candidates for surgical replacement.
Methods
At 25 centers, we randomly assigned 699 high-risk patients with severe aortic stenosis 
to undergo either transcatheter aortic-valve replacement with a balloon-expandable 
bovine pericardial valve (either a transfemoral or a transapical approach) or surgical 
replacement. The primary end point was death from any cause at 1 year. The primary 
hypothesis was that transcatheter replacement is not inferior to surgical replacement.
Results
The rates of death from any cause were 3.4% in the transcatheter group and 6.5% in 
the surgical group at 30 days (P = 0.07) and 24.2% and 26.8%, respectively, at 1 year 
(P = 0.44), a reduction of 2.6 percentage points in the transcatheter group (upper 
limit of the 95% confidence interval, 3.0 percentage points; predefined margin, 7.5 
percentage points; P = 0.001 for noninferiority). The rates of major stroke were 3.8% 
in the transcatheter group and 2.1% in the surgical group at 30 days (P = 0.20) and 
5.1% and 2.4%, respectively, at 1 year (P = 0.07). At 30 days, major vascular compli-
cations were significantly more frequent with transcatheter replacement (11.0% vs. 
3.2%, P<0.001); adverse events that were more frequent after surgical replacement 
included major bleeding (9.3% vs. 19.5%, P<0.001) and new-onset atrial fibrillation 
(8.6% vs. 16.0%, P = 0.006). More patients undergoing transcatheter replacement had 
an improvement in symptoms at 30 days, but by 1 year, there was not a significant 
between-group difference.
Conclusions
In high-risk patients with severe aortic stenosis, transcatheter and surgical proce-
dures for aortic-valve replacement were associated with similar rates of survival at 
1 year, although there were important differences in periprocedural risks. (Funded by 
Edwards Lifesciences; Clinical Trials.gov number, NCT00530894.)
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A fter the appearance of symptoms, aortic stenosis is associated with a high rate of death if left untreated.1-10 Although 
surgical aortic-valve replacement improves symp-
toms and survival,11-15 observational studies have 
identified various subgroups of patients (i.e., those 
with an advanced age and those with poor left 
ventricular function or other coexisting disorders) 
who are at increased risk for operative complica-
tions or death.16-21 In such patients, a less invasive 
treatment may be a desirable alternative.
Transcatheter aortic-valve replacement treats 
aortic stenosis by displacing and functionally re-
placing the native valve with a bioprosthetic valve 
delivered on a catheter through the femoral artery 
(transfemoral placement) or the left ventricular 
apex (transapical placement).22-34 In the random-
ized Placement of Aortic Transcatheter Valves 
(PARTNER) trial, a subgroup of patients with aor-
tic stenosis who were not candidates for surgical 
aortic-valve replacement and who underwent trans-
femoral placement had an improvement of 20% in 
the 1-year survival rate and also had reduced symp-
toms.35 This report describes results for the high-
risk subgroup of patients in the PARTNER trial 
who were still candidates for surgical valve replace-
ment and who were randomly assigned to undergo 
either transcatheter or surgical replacement of the 
aortic valve.
Me thods
Patients
From May 11, 2007, through August 28, 2009, we 
enrolled 699 patients with severe aortic stenosis 
and cardiac symptoms (New York Heart Associa-
tion [NYHA] class II function or worse) at 22 cen-
ters in the United States, 2 centers in Canada, and 
1 center in Germany. All the patients were consid-
ered to be candidates for conventional surgical aor-
tic-valve repair. Severe aortic stenosis was defined 
as an aortic-valve area of less than 0.8 cm2 plus 
either a mean valve gradient of at least 40 mm Hg 
or a peak velocity of at least 4.0 m per second. Pa-
tients were deemed to be at high risk for operative 
complications or death on the basis of coexisting 
conditions that were associated with a risk of death 
of at least 15% by 30 days after the procedure. The 
final determination of high operative risk was 
made by surgeons at each study center, but we 
used as a guideline a score of at least 10% on the 
risk model developed by the Society for Thoracic 
Surgeons, which uses an algorithm that is based 
on the presence of coexisting illnesses in order to 
estimate the 30-day operative mortality. Less than 
5% of patients in the population from which the 
algorithm was derived had a predicted operative 
risk (risk score) of more than 10%.36
Exclusion criteria were a bicuspid or noncalci-
fied valve, coronary artery disease requiring revas-
cularization, a left ventricular ejection fraction of 
less than 20%, an aortic annulus diameter of less 
than 18 mm or more than 25 mm, severe (4+) 
mitral or aortic regurgitation, a recent neuro-
logic event, and severe renal insufficiency. Com-
plete inclusion and exclusion criteria are provided 
in Table 1 in the Supplementary Appendix (avail-
able with the full text of this article at NEJM.org).
The executive committee conducted Web-based 
conference calls to review and approve all poten-
tial study participants before randomization. Of 
the 3105 patients who were screened at all the 
study centers and by the executive committee, 34% 
underwent randomization, and 23% were assigned 
to the high-risk subgroup for which the results 
are reported here.
Study Device and Procedure
The SAPIEN heart-valve system (Edwards Life-
sciences) and the transcatheter-replacement pro-
cedure have been described previously35 (Fig. 1, 
and video, available at NEJM.org). Patients who 
were assigned to the transcatheter group under-
went either transfemoral or transapical placement 
of the aortic valve on the basis of whether periph-
eral arteries could accommodate the large French 
sheaths required (22 French for the 23-mm valve 
and 24 French for the 26-mm valve). Transapical 
placement was performed through a small inter-
costal incision over the left ventricular apex with 
the use of a dedicated delivery catheter and the 
same Edwards SAPIEN valve. Patients received hep-
arin during the procedure and dual antiplatelet 
therapy (aspirin and clopidogrel) for 6 months 
afterward.
Study Design
The study design and data-management practices 
have been described previously35 (Fig. 1 and Table 
2 in the Supplementary Appendix). The study pro-
tocol and statistical analysis plan are available at 
NEJM.org. Patients first underwent evaluation of 
their peripheral arteries before randomization in 
order to separate those eligible for transfemoral 
placement from those who would require transapi-
cal placement (Fig. 2 in the Supplementary Ap-
A video  showing 
 transcatheter 
aortic-valve 
 replacement 
is available 
at NEJM.org 
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pendix). According to the results of this evalua-
tion, 492 patients were then categorized as being 
eligible for transfemoral placement (transfemoral-
placement cohort), and 207 patients were catego-
rized as being eligible for transapical placement 
(transapical-placement cohort). With the use of 
computer-generated randomized blocks at each site 
and for each subgroup, patients in the two cohorts 
were then randomly assigned to undergo either 
transcatheter replacement (348 patients) or surgi-
cal replacement (351 patients). The intention-to-
treat analysis started at the time of randomiza-
tion, and the as-treated analysis started at the time 
of induction of anesthesia in the procedure room.
The trial was approved by the institutional re-
view board at each site. All patients provided writ-
ten informed consent.
Study Oversight
The study was designed by the sponsor, Edwards 
Life sciences, and by the executive committee, which 
included the first two authors, three intervention-
al cardiologists (who were the coprincipal inves-
tigators), along with six other academic authors 
(three cardiac surgeons). The sponsor funded the 
studies and participated in the selection and man-
agement of the sites, the collection of data, and 
data monitoring. The executive committee met in 
person every 6 to 8 weeks to monitor all aspects 
of the conduct of the trial. Members of the execu-
tive committee had unrestricted access to the data 
 after the database was locked and prepared all 
drafts of the manuscript. The sponsor’s statistician 
performed the data analysis, which was duplicated 
and verified by the independent statisticians at the 
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Figure 1. Transcatheter Aortic-Valve Replacement.
The transcatheter valve is positioned at the level of the native aortic valve during the final step of valve replacement, 
when the balloon is inflated within the native valve during a brief period of rapid ventricular pacing. The delivery system 
is shown after it has traversed the aorta retrograde over a guidewire from its point of insertion in the femoral artery 
(transfemoral placement). Before balloon inflation, the valve and balloon are collapsed on the catheter (dark blue) and 
fit within the sheath (blue). After balloon inflation, the calcified native valve (upper panel) is replaced by the expanded 
transcatheter valve (lower panel, shown in short-axis view from the aortic side of the valve).
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London School of Hygiene and Tropical Medicine. 
The first author made the decision to submit the 
manuscript for publication, with the consent of all 
the other authors. The executive committee attests 
to the integrity of the trial and the completeness 
and accuracy of the reported data.
Study End Points
The primary end point was the rate of death from 
any cause at 1 year in the intention-to-treat popu-
lation. All patients were followed for at least 1 year. 
Crossover between the two study groups was not 
permitted, except when findings or events during 
the assigned procedure prevented the planned 
treatment. Prespecified secondary end points in-
cluded death from cardiovascular causes, NYHA 
functional class, repeat hospitalization because of 
valve- or procedure-related clinical deterioration, 
myocardial infarction, stroke, acute kidney injury, 
vascular complications, bleeding, 6-minute walk 
distance, and valve performance (as assessed on 
echocardiography). In a retrospective analysis of 
neurologic events adjudicated by the clinical events 
committee, major stroke was defined by a score 
of at least 2 on the modified Rankin scale (which 
ranges from 0 to 6, with higher scores indicating 
greater disability).37 Specific definitions of end 
points are provided in Table 3 in the Supplemen-
tary Appendix. Patients were followed during the 
index hospitalization and at 30 days, 6 months, 
1 year, and yearly thereafter.
Statistical Analysis
We determined that a sample of 650 patients 
would provide a power of at least 85% to show 
the noninferiority of transcatheter replacement, 
as compared with surgical replacement, with re-
spect to the primary end point, assuming a 1-year 
rate of death of 29% in the transcatheter group 
and 32% in the surgical group. Noninferiority 
would be established if the upper limit of the one-
sided 95% confidence interval for the between-
group difference in mortality was less than 7.5 
percentage points, at an alpha level of 0.05. We 
also determined that enrollment of 450 patients 
undergoing transfemoral placement would pro-
vide a power of at least 85% to show the noninfe-
riority of transcatheter replacement, as compared 
with surgical replacement, on the assumption of 
a 1-year rate of death of 25% in the transcatheter 
group and 30% in the surgical group, with the 
same 7.5 percentage points noninferiority mar-
gin. Additional assumptions in sample-size com-
putations were that 65% of all procedures would 
be transfemoral placement, that follow-up would 
continue for at least 12 months after enrollment 
of the last patient, and that 10% of patients would 
be lost to follow-up.
We used Fisher’s exact test to compare categor-
ical variables. Continuous variables, presented as 
means (±SD), were compared with the use of Stu-
dent’s t-test. Primary data analysis was performed 
in the intention-to-treat population, regardless of 
the treatment that was actually received. The re-
sults of as-treated analyses for primary and sec-
ondary end points are also provided. Time-to-event 
analyses, based on all available follow-up data, 
were performed with the use of Kaplan–Meier es-
timates and were compared between groups with 
the use of the log-rank test. A generalized linear 
model was used to calculate risk ratios in the sub-
group analyses and to test for interactions. All 
statistical analyses were performed with the use 
of SAS software, version 9.2.
R esult s
Patients
In the transcatheter group, 244 patients were as-
signed to undergo transfemoral placement, and 
104 were assigned to undergo transapical place-
ment. A total of 351 patients were assigned to un-
dergo surgical replacement, separately randomized 
to control groups in the transfemoral-placement 
cohort (248 patients) and the transapical-place-
ment cohort (103 patients). Patients were followed 
for at least 1 year (median, 1.4 years; maximum, 
3.3 years). The baseline characteristics of the pa-
tients in the two study groups were well balanced 
(Table 1). The high overall mean score (11.8%) on 
the risk model of the Society of Thoracic Surgeons 
indicated a high operative risk. As compared with 
patients in the transfemoral-placement cohort, pa-
tients in the transapical-placement cohort had sig-
nificantly increased rates of previous coronary-
artery bypass grafting (CABG), cerebrovascular 
disease, and peripheral vascular disease, despite 
the similar overall Society of Thoracic Surgeons 
scores in the two groups (Table 4 in the Supple-
mentary Appendix).
Among the 699 patients who were randomly 
assigned to a study group, 42 did not undergo the 
assigned procedure (4 in the transcatheter group 
and 38 in the surgical group). The main reasons 
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for nontreatment were withdrawal from the study 
or a decision not to undergo surgical therapy (28 
patients) (Table 5 in the Supplementary Appen-
dix). The baseline risk profile of patients who did 
not undergo the assigned treatment was similar 
to that of treated patients. The mean (±SE) interval 
between randomization and treatment was sig-
nificantly longer in the surgical group than in the 
transcatheter group (15.6±1.1 days vs. 10.6±0.7 
days, P<0.001).
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Transcatheter 
Replacement
(N = 348)
Surgical 
Replacement  
(N = 351) P Value
Age — yr 83.6±6.8 84.5±6.4 0.07
Male sex — no./total no. (%) 201/348 (57.8) 198/349 (56.7) 0.82
Society of Thoracic Surgeons score† 11.8±3.3 11.7±3.5 0.61
Logistic EuroSCORE† 29.3±16.5 29.2±15.6 0.93
New York Heart Association class — no./total no. (%) 0.79
II 20/348 (5.7) 21/349 (6.0)
III or IV 328/348 (94.3) 328/349 (94.0)
Coronary artery disease — no./total no. (%) 260/347 (74.9) 266/346 (76.9) 0.59
Previous myocardial infarction — no./total no. (%) 92/343 (26.8) 103/343 (30.0) 0.40
Previous CABG — no./total no. (%) 147/345 (42.6) 152/344 (44.2) 0.70
Previous PCI — no./total no. (%) 116/341 (34.0) 110/338 (32.5) 0.68
Previous balloon aortic valvuloplasty — no./total no. (%) 46/344 (13.4) 35/344 (10.2) 0.24
Cerebral vascular disease — no./total no. (%) 95/324 (29.3) 87/317 (27.4) 0.60
Peripheral vascular disease — no./total no. (%) 148/344 (43.0) 142/341 (41.6) 0.76
COPD — no./total no. (%)
Any 151/348 (43.4) 151/351 (43.0) 0.94
Oxygen-dependent 32/348 (9.2) 25/351 (7.1) 0.34
Creatinine level >2 mg/dl (177 μmol/liter) — no./total no. (%) 38/343 (11.1) 24/344 (7.0) 0.06
Atrial fibrillation — no./total no. (%) 80/196 (40.8) 73/171 (42.7) 0.75
Permanent pacemaker — no./total no. (%) 69/345 (20.0) 76/347 (21.9) 0.58
Pulmonary hypertension — no./total no. (%) 125/295 (42.4) 110/302 (36.4) 0.15
Frail condition — no./total no. (%) 46/295 (15.6) 53/301 (17.6) 0.58
Extensively calcified aorta — no./total no. (%) 2/348 (0.6) 4/351 (1.1) 0.69
Deleterious effects of chest-wall irradiation — no./total no. (%) 3/348 (0.9) 3/351 (0.9) 1.00
Chest-wall deformity — no./total no. (%) 0 1/351 (0.3) 1.00
Liver disease — no./total no. (%) 7/344 (2.0) 9/346 (2.6) 0.80
Aortic-valve area — cm2 0.7±0.2 0.6±0.2 0.13
Aortic-valve gradient — mm Hg 42.7±14.6 43.5±14.3 0.45
Left ventricular ejection fraction — % 52.5±13.5 53.3±12.8 0.45
Moderate or severe mitral regurgitation — no./total no. (%) 66/334 (19.8) 71/333 (21.3) 0.63
* Plus–minus values are means ±SD. CABG denotes coronary-artery bypass grafting, COPD chronic obstructive pulmo-
nary disease, and PCI percutaneous coronary intervention.
† Scores on the risk model of the Society of Thoracic Surgeons (STS) and scores on the logistic EuroSCORE scale are 
algorithms that are based on the presence of coexisting illnesses in order to predict the 30-day operative mortality. The 
STS score equals the predicted mortality expressed as a percentage. Less than 5% of patients in the population on 
which the STS algorithm is based had a predicted operative mortality (risk score) of more than 10%. The EuroSCORE 
 algorithm generates a score that is typically two to three times the STS score for the same patient.
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Procedure Outcomes
A total of 4 patients died during the procedure 
(3 in the transcatheter group and 1 in the surgi-
cal group) (Table 6 in the Supplementary Appen-
dix). The transcatheter procedure was either abort-
ed or converted to open surgery in 16 of 348 
patients (4.6%) as a result of new intraprocedural 
findings (e.g., an aortic annulus diameter >25 mm), 
failure to obtain femoral access, or procedural com-
plications. Among these 16 patients, 9 immediately 
underwent open surgery (including 1 who died), 
2 underwent open surgery more than 30 days later, 
and 5 did not undergo valve replacement (including 
3 who died). One patient in the surgical group un-
derwent transapical replacement as a result of an 
extremely calcified aorta, which was discovered 
during the surgical procedure. Multiple trans-
catheter valves (≥2) were implanted in 7 patients 
because of valve embolization (in 2 patients) or re-
sidual aortic regurgitation (in 5 patients in whom 
a second valve was placed within the first valve); 
3 of these 7 patients died. Among 7 other patients 
with valve embolization, transcatheter placement 
was aborted in 2 patients and was converted to 
open surgery in 5 patients. Late interventions (>30 
days) after transcatheter placement included bal-
loon aortic valvuloplasty for paravalvular regurgi-
tation in 2 patients and conversion to transapical 
placement in 1 patient.
Mortality and Stroke
Since there were greater delays in treatment and 
more withdrawals or decisions to forgo treatment 
in the surgical group, both intention-to-treat and 
as-treated analyses are presented for the key study 
end points. In the intention-to-treat analysis, the 
rates of death from any cause at 30 days were 3.4% 
in the transcatheter group and 6.5% in the surgical 
group (P = 0.07) (Table 2). In the as-treated analysis, 
the rates of death were 5.2% in the transcathe-
ter group and 8.0% in the surgical group (P = 0.15) 
(Table 7 in the Supplementary Appendix). Among 
patients in the transfemoral-placement cohort, the 
rates of death from any cause at 30 days were 
3.3% in the transcatheter group and 6.2% in the 
surgical group in the intention-to-treat analysis 
(P = 0.13) (Table 8 in the Supplementary Appendix) 
and 3.7% and 8.2%, respectively, in the as-treated 
analysis (P = 0.046) (Table 9 in the Supplementary 
Appendix). Among patients in the transapical-
placement cohort, the rates of death at 30 days 
were 3.8% in the transcatheter group and 7.0% in 
the surgical group in the intention-to-treat analy-
sis (P = 0.32) (Table 10 in the Supplementary Ap-
pendix) and 8.7% and 7.6%, respectively, in the 
as-treated analysis (P = 0.79) (Table 11 in the Sup-
plementary Appendix).
At 1 year, the rate of death from any cause in 
the intention-to-treat population (the primary 
study end point) was 24.2% in the transcatheter 
group as compared with 26.8% in the surgical 
group (P = 0.44). The difference of -2.6 percentage 
points (two-sided 95% confidence interval [CI], 
-9.3 to 4.1; upper limit of the one-sided 95% CI, 
3.0 percentage points) was within the prespecified 
noninferiority margin of 7.5 percentage points 
(P = 0.001 for noninferiority) (Table 2 and Fig. 2). 
Similarly, there were no significant differences 
in the rates of death between the transfemoral-
placement cohort and the surgical group (powered 
comparison) (rate difference, -4.2 percentage 
points; upper limit of the 95% CI, 2.3 percentage 
points; P = 0.002 for noninferiority) (Fig. 2B, and 
Table 8 in the Supplementary Appendix) or be-
tween the transapical-placement cohort and the 
surgical group (unpowered comparison) (Fig. 2C, 
and Table 10 in the Supplementary Appendix).
According to the risk model of the Society of 
Thoracic Surgeons,36 the expected 30-day rate of 
death in the surgical group was 11.8%. The ac-
tual rate of death among patients who underwent 
surgery (as-treated population) was 8.0%, indicat-
ing a better-than-anticipated surgical outcome. 
There were no important differences in surgical 
outcomes among centers or individual surgeons.
Rates of all neurologic events (i.e., all strokes 
and transient ischemic attacks) were higher in the 
transcatheter group than in the surgical group at 
30 days (5.5% vs. 2.4%, P = 0.04) and at 1 year 
(8.3% vs. 4.3%, P = 0.04). Rates of major stroke 
were 3.8% in the transcatheter group and 2.1% in 
the surgical group at 30 days (P = 0.20) and 5.1% 
and 2.4%, respectively, at 1 year (P = 0.07). The rates 
of a composite of death from any cause or major 
stroke were similar in the transcatheter group and 
the surgical group at 30 days (6.9% and 8.2%, re-
spectively; P = 0.52) and at 1 year (26.5% and 28.0%, 
respectively; P = 0.68) (Table 2 and Fig. 2).
Subgroup analyses with interaction testing 
were performed to determine whether the be-
tween-group mortality comparisons were con-
sistent across 10 subgroups of patients (Fig. 3). 
There were significant interactions for the rate 
of death at 1 year according to sex and status 
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with respect to previous CABG, favoring trans-
catheter replacement in women and in patients 
without a history of CABG.
Other Clinical Outcomes
At 30 days, the transcatheter group had a signif-
icantly higher rate of major vascular complica-
tions than did the surgical group (11.0% vs. 3.2%, 
P<0.001) but had lower rates of major bleeding 
events (9.3% vs. 19.5%, P<0.001) and new-onset 
atrial fibrillation (8.6% vs. 16.0%), P = 0.006) (Ta-
ble 2).
At 30 days, more patients in the transcatheter 
group than in the surgical group had a reduction 
in symptoms to NYHA class II or lower (P<0.001) 
(Fig. 4). Among patients who could perform 
6-minute walk tests, patients in the transcatheter 
group walked farther than those in the surgical 
group (P = 0.002) (Fig. 3 in the Supplementary 
Appendix). At 1 year, patients in the two study 
groups had an improvement in cardiac symp-
toms and the 6-minute walk distance, with no 
evidence of significant between-group differ-
ences. Patients in the transcatheter group had 
a significantly shorter length of stay in the in-
tensive care unit (3 days, vs. 5 days in the surgi-
cal group) and a shorter index hospitalization 
(8 vs. 12 days) (P<0.001 for both comparisons).
Table 2. Clinical Outcomes at 30 Days and 1 Year in the Intention-to-Treat Population.*
Outcome 30 Days 1 Year
Transcatheter 
Replacement  
(N = 348)
Surgical 
Replacement  
(N = 351) P Value
Transcatheter 
Replacement 
(N = 348)
Surgical 
Replacement 
(N = 351) P Value
no. of patients (%) no. of patients (%)
Death
From any cause 12 (3.4) 22 (6.5) 0.07 84 (24.2) 89 (26.8) 0.44
From cardiac causes 11 (3.2) 10 (3.0) 0.90 47 (14.3) 40 (13.0) 0.63
Repeat hospitalization 15 (4.4) 12 (3.7) 0.64 58 (18.2) 45 (15.5) 0.38
Death or repeat hospitalization 25 (7.2) 33 (9.7) 0.24 120 (34.6) 119 (35.9) 0.73
Stroke or transient ischemic attack
Either 19 (5.5) 8 (2.4) 0.04 27 (8.3) 13 (4.3) 0.04
Transient ischemic attack 3 (0.9) 1 (0.3) 0.33 7 (2.3) 4 (1.5) 0.47
Stroke
Minor 3 (0.9) 1 (0.3) 0.34 3 (0.9) 2 (0.7) 0.84
Major 13 (3.8) 7 (2.1) 0.20 17 (5.1) 8 (2.4) 0.07
Death from any cause or major stroke 24 (6.9) 28 (8.2) 0.52 92 (26.5) 93 (28.0) 0.68
Myocardial infarction 0 2 (0.6) 0.16 1 (0.4) 2 (0.6) 0.69
Vascular complication
Any 59 (17.0) 13 (3.8) <0.001 62 (18.0) 16 (4.8) <0.001
Major 38 (11.0) 11 (3.2) <0.001 39 (11.3) 12 (3.5) <0.001
Acute kidney injury
Creatinine >3 mg/dl (265 μmol/liter) 4 (1.2) 4 (1.2) 0.95 12 (3.9) 8 (2.7) 0.41
Renal-replacement therapy 10 (2.9) 10 (3.0) 0.95 18 (5.4) 20 (6.5) 0.56
Major bleeding 32 (9.3) 67 (19.5) <0.001 49 (14.7) 85 (25.7) <0.001
Endocarditis 0 1 (0.3) 0.32 2 (0.6) 3 (1.0) 0.63
New-onset atrial fibrillation† 30 (8.6) 56 (16.0) 0.006 42 (12.1) 60 (17.1) 0.07
New pacemaker 13 (3.8) 12 (3.6) 0.89 19 (5.7) 16 (5.0) 0.68
* All percentages are Kaplan–Meier estimates at the specific time point and thus do not equal the number of patients divided by the total 
number in the study group.
† The presence of new-onset atrial fibrillation was determined in an electrocardiography core laboratory.
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Echocardiographic Findings
Aortic-valve gradients and areas improved signifi-
cantly after the two procedures at both 30 days 
and 1 year (Table 12 in the Supplementary Ap-
pendix). At 1 year, transcatheter replacement 
was slightly superior to surgical replacement 
with respect to the mean aortic-valve gradient 
(10.2±4.3 mm Hg vs. 11.5±5.4 mm Hg, P = 0.008) 
and mean valve area (1.59±0.48 cm2 vs. 1.44±
0.47 cm2, P = 0.002). Moderate or severe paraval-
vular regurgitation was more frequent in the 
transcatheter group than in the surgical group at 
30 days (12.2% vs. 0.9%) and at 1 year (6.8% vs. 
1.9%) (P<0.001 for both comparisons).
Discussion
In this study, we affirmed the primary noninferi-
ority hypothesis that was tested in the original 
PARTNER trial: transcatheter aortic-valve replace-
ment was similar to surgical replacement with re-
spect to rates of death from any cause at 1 year 
among patients with aortic stenosis who were at 
high risk for increased operative complications and 
death. The end point of the rate of death at 1 year 
among patients in the transfemoral-placement 
cohort (powered comparison) was also noninferior 
in the transcatheter group, as compared with the 
surgical group.
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Figure 2. Time-to-Event Curves for the Primary End Point and Other Selected End Points.
Time-to-event curves are shown for death from any cause in all patients (Panel A), in the transfemoral-placement cohort (Panel B), and 
in the transapical-placement cohort (Panel C) and for a composite of death or major stroke (Panel D) among patients who were ran-
domly assigned to undergo either transcatheter aortic-valve replacement (TAVR) or surgical aortic-valve replacement (AVR). The event 
rates were calculated with the use of Kaplan–Meier methods and compared with the use of the log-rank test.
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Procedure-specific outcomes are best revealed 
in early (30-day) results. The surgical outcomes in 
this trial were excellent, as compared with those 
in studies involving high-risk patients with aortic 
stenosis.16-21 In the as-treated population, the ra-
tio of observed operative mortality to predicted 
mortality (according to the risk model of the 
Society of Thoracic Surgeons) was 0.68. Rates of 
death in the transcatheter group at 30 days (3.4% 
in the intention-to-treat analysis and 5.2% in the 
as-treated analysis) were also excellent, as com-
pared with earlier results in the PARTNER trial 
in patients who were not candidates for surgical 
valve replacement35 and with data from other reg-
istries of transcatheter replacement.24-26,29-34 As in 
previous observational studies of transcatheter 
1.0 2.0
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Figure 3. Subgroup Analyses for Death from Any Cause at 1 Year.
Subgroup analyses are shown for the primary end point of death from any cause at 1 year among patients in the intention-to-treat popu-
lation who were randomly assigned to undergo either transcatheter aortic-valve replacement or surgical aortic-valve replacement. The 
P value for interaction represents the likelihood of interaction between the variable and the relative treatment effect. The body-mass index 
is the weight in kilograms divided by the square of the height in meters. CABG denotes coronary-artery bypass grafting, and STS Society 
of Thoracic Surgeons.
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replacement,27,28,30,31,34 the rates of death at 30 days 
were higher among patients who had undergone 
transapical placement than among those who 
had undergone transfemoral placement. Possible 
reasons for these increased rates in the transapi-
cal cohort include an increased rate of coexist-
ing disorders, a more protracted learning curve for 
surgeons, a smaller number of patients who were 
evaluated, and important procedural differences. 
Procedure-specific complications in the transcath-
eter group included conversion to an open surgical 
procedure, valve embolization, and reintervention 
for regurgitation of bioprosthetic valves. The re-
sults of the subgroup analyses, which must always 
be interpreted with caution, suggest that trans-
catheter replacement was associated with lower 
mortality than surgical replacement among wom-
en and patients without a history of CABG.
Clinical benefits of transcatheter replacement 
included significantly shorter stays in the inten-
sive care unit and in the hospital. In addition, the 
NYHA functional class and 6-minute walk dis-
tance were strikingly improved at 1 year in the two 
study groups, although at 30 days, the benefits 
were greater with transcatheter replacement than 
with surgical replacement.
The approximate doubling in the rate of all new 
neurologic events (including major strokes) after 
transcatheter replacement, as compared with sur-
gical replacement, remains a concern and is con-
sistent with previous findings in the PARTNER 
trial35 and with recent studies indicating an in-
creased rate of new cerebral perfusion abnormali-
ties associated with transcatheter replacement.38-40
Most strokes appeared to be procedure-related and 
embolic. Rates of stroke were similar whether 
the access was transfemoral or transapical. Despite 
a higher frequency of stroke with transcatheter 
replacement, the composite end point of death 
from any cause or major stroke was similar in the 
two study groups at both 30 days and 1 year. Fu-
ture studies will determine whether delivery sys-
tems with smaller diameters, procedural changes, 
or embolic-protection devices can reduce the inci-
dence of stroke after transcatheter replacement.
Other periprocedural hazards reflected the in-
herent differences between an open operation and 
a transcatheter procedure. As expected, open sur-
gery was associated with more frequent episodes 
of major bleeding and new-onset atrial fibrillation. 
There were more major vascular complications as-
sociated with transcatheter replacement. It is pos-
sible that the smaller-catheter systems already in 
use, combined with increased surgical experience 
and improved case selection, will reduce vascular 
complications.
Bioprosthetic-valve gradients and orifice areas 
were slightly better after transcatheter replacement 
than after surgical replacement, probably because 
of the less bulky support frame with transcatheter 
replacement. However, transcatheter replacement 
resulted in much more frequent paravalvular aor-
tic regurgitation. Although this condition was sta-
ble at 1 year, repeat intervention was required in 
some cases, and the long-term clinical consequenc-
es are unknown.
Our study has several limitations. First, with-
drawals and decisions to forgo the procedure 
among patients who were assigned to undergo 
surgical replacement were unexpectedly frequent, 
and approximately 5% of patients who were as-
signed to the transcatheter group did not undergo 
the procedure. Consequently, a balanced perspec-
tive on early procedure-related outcomes requires 
an analysis of both the intention-to-treat and as-
treated study populations. Nevertheless, for the 
main comparisons of rates of death, neurologic 
events, and procedural hazards, the two study 
groups did not differ significantly in the as-treated 
population. Second, a definitive assessment of the 
durability of the prosthetic valves used in trans-
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Figure 4. Symptom Status.
Shown is the New York Heart Association (NYHA) functional status (accord-
ing to time point) for 697 of 699 patients who were randomly assigned to 
undergo either transcatheter aortic-valve replacement (TAVR) or surgical 
aortic-valve replacement (AVR).
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catheter replacement awaits longer follow-up. 
Third, we used an early version of the transcath-
eter device, predominantly in centers with no pre-
vious experience with the procedure. Finally, the 
study had insufficient statistical power to reach 
robust conclusions with respect to specific sub-
groups of patients, including any possible differ-
ences in outcome between the transapical and 
transfemoral procedures.
In conclusion, we have shown that in patients 
with aortic stenosis who are at high risk for op-
erative complications and death, surgical aortic-
valve replacement and balloon-expandable trans-
catheter replacement were associated with similar 
mortality at 30 days and 1 year and produced 
similar improvements in cardiac symptoms. Our 
findings indicate that transcatheter replacement 
is an alternative to surgical replacement in a well-
chosen, high-risk subgroup of patients with aortic 
stenosis. In the absence of long-term follow-up 
data, recommendations to individual patients must 
balance the appeal of avoiding the known risks of 
open-heart surgery against the less invasive trans-
catheter approach, which has different and less 
well understood risks, particularly with respect to 
stroke. Additional randomized trials will be re-
quired to determine whether transcatheter replace-
ment is equivalent to surgical replacement with 
respect to the clinical benefit for lower-risk pa-
tients with aortic stenosis.
Supported by Edwards Lifesciences.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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